These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systemic antifungal agents. Drug interactions of clinical significance. Albengres E; Le Louët H; Tillement JP Drug Saf; 1998 Feb; 18(2):83-97. PubMed ID: 9512916 [TBL] [Abstract][Full Text] [Related]
3. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Haria M; Bryson HM; Goa KL Drugs; 1996 Apr; 51(4):585-620. PubMed ID: 8706596 [TBL] [Abstract][Full Text] [Related]
4. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Gupta AK; Shear NH Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975 [TBL] [Abstract][Full Text] [Related]
8. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Tucker RM; Denning DW; Hanson LH; Rinaldi MG; Graybill JR; Sharkey PK; Pappagianis D; Stevens DA Clin Infect Dis; 1992 Jan; 14(1):165-74. PubMed ID: 1315160 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Back DJ; Tjia JF Br J Clin Pharmacol; 1991 Nov; 32(5):624-6. PubMed ID: 1659439 [TBL] [Abstract][Full Text] [Related]
10. Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. Wingfield AB; Fernandez-Obregon AC; Wignall FS; Greer DL Br J Dermatol; 2004 Jan; 150(1):119-26. PubMed ID: 14746625 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of antifungal agents in onychomycoses. Debruyne D; Coquerel A Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of systemic fungal infections. Walsh TJ Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615 [TBL] [Abstract][Full Text] [Related]
13. Liver injury associated with ketoconazole: review of the published evidence. Greenblatt HK; Greenblatt DJ J Clin Pharmacol; 2014 Dec; 54(12):1321-9. PubMed ID: 25216238 [TBL] [Abstract][Full Text] [Related]
14. Opportunistic fungal infections in patients with acquired immune deficiency syndrome. Viviani MA Chemotherapy; 1992; 38 Suppl 1():35-42. PubMed ID: 1319314 [TBL] [Abstract][Full Text] [Related]
15. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Singh S; Chandra U; Anchan VN; Verma P; Tilak R Br J Dermatol; 2020 Nov; 183(5):840-846. PubMed ID: 32538466 [TBL] [Abstract][Full Text] [Related]
16. Antifungal agents. Part II. The azoles. Terrell CL Mayo Clin Proc; 1999 Jan; 74(1):78-100. PubMed ID: 9987539 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral antifungals and their clinical implications. Heykants J; Van Peer A; Lavrijsen K; Meuldermans W; Woestenborghs R; Cauwenbergh G Br J Clin Pract Suppl; 1990 Sep; 71():50-6. PubMed ID: 1965419 [TBL] [Abstract][Full Text] [Related]
18. Oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis : case reports and review of the literature. Nikkels AF; Nikkels-Tassoudji N; Piérard GE Am J Clin Dermatol; 2006; 7(5):327-31. PubMed ID: 17007544 [TBL] [Abstract][Full Text] [Related]
19. Azoles, allylamines and drug metabolism. Back DJ; Tjia JF; Abel SM Br J Dermatol; 1992 Feb; 126 Suppl 39():14-8. PubMed ID: 1311943 [TBL] [Abstract][Full Text] [Related]
20. New antifungal agents for the systemic mycoses. Ringel SM Mycopathologia; 1990 Feb; 109(2):75-87. PubMed ID: 2157984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]